http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 13 Jul 2026 06:04:02 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/New+Coverage/Leerink+Starts+Whitehawk+Therapeutics+%28WHWK%29+at+Outperform/26759194.html <p>Leerink initiates coverage on Whitehawk Therapeutics (NASDAQ: WHWK) with a Outperform rating and a price target of $9.00.</p> <p>For an analyst ratings summary and ratings history on Whitehawk Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=WHWK">click here</a>. For more ratings news on Whitehawk Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=WHWK&amp;type=analyst">click here</a>.</p> <p>Shares of Whitehawk Therapeutics closed at $3.97 yesterday.</p> http://www.streetinsider.com/New+Coverage/Leerink+Starts+Whitehawk+Therapeutics+%28WHWK%29+at+Outperform/26759194.html Mon, 13 Jul 2026 06:04:02 -0400 WHWK http://www.streetinsider.com/Corporate+News/Biocytogen+and+Whitehawk+team+up+on+bispecific+antibody+ADC+programs/26738868.html <p>Biocytogen and Whitehawk Therapeutics (Nasdaq: WHWK) announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC), according to a press release from the companies.</p><p>Under the agreement, Biocytogen will provide access to up to five bispecific antibodies generated through its RenLite® platform, which uses a common light-chain design to discover and optimize fully human bispecific antibodies. Whitehawk will evaluate these antibodies in combination with its ADC linker-payload platform technologies and holds the option to advance any resulting BsADC candidates into its pipeline, retaining global rights and full program control over any candidates it elects to pursue.</p><p>Biocytogen will receive an upfront payment http://www.streetinsider.com/Corporate+News/Biocytogen+and+Whitehawk+team+up+on+bispecific+antibody+ADC+programs/26738868.html Tue, 07 Jul 2026 08:01:09 -0400 WHWK http://www.streetinsider.com/Press+Releases/Biocytogen+and+Whitehawk+Therapeutics+Enter+Global+Collaboration+for+Bispecific+Antibody+ADC+Development/26738739.html <p> BOSTON &amp; MORRISTOWN, N.J.--(BUSINESS WIRE)-- Biocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. (“Whitehawk,” Nasdaq: WHWK) today announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocytogen will provide access to up to five bispecific antibodies using its proprietary RenLite® platform, and Whitehawk will evaluate these in combination with its ADC linker-payload platform technologies. Whitehawk then has the option to advance any resulting BsADC candidates as part of its pipeline. </p><p> Based on a common light-chain design, RenLite® supports the discovery, screening, and optimization of fully human bispecific antibodies across diverse target combinations, while reducing the risk http://www.streetinsider.com/Press+Releases/Biocytogen+and+Whitehawk+Therapeutics+Enter+Global+Collaboration+for+Bispecific+Antibody+ADC+Development/26738739.html Tue, 07 Jul 2026 08:00:00 -0400 02315 688796 O.37125755 O.55107896 WHWK http://www.streetinsider.com/Press+Releases/Biocytogen+and+Whitehawk+Therapeutics+Enter+Global+Collaboration+for+Bispecific+Antibody+ADC+Development/26738739.html <p> BOSTON &amp; MORRISTOWN, N.J.--(BUSINESS WIRE)-- Biocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. (“Whitehawk,” Nasdaq: WHWK) today announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocytogen will provide access to up to five bispecific antibodies using its proprietary RenLite® platform, and Whitehawk will evaluate these in combination with its ADC linker-payload platform technologies. Whitehawk then has the option to advance any resulting BsADC candidates as part of its pipeline. </p><p> Based on a common light-chain design, RenLite® supports the discovery, screening, and optimization of fully human bispecific antibodies across diverse target combinations, while reducing the risk http://www.streetinsider.com/Press+Releases/Biocytogen+and+Whitehawk+Therapeutics+Enter+Global+Collaboration+for+Bispecific+Antibody+ADC+Development/26738739.html Tue, 07 Jul 2026 08:00:00 -0400 02315 688796 O.37125755 O.55107896 WHWK http://www.streetinsider.com/Press+Releases/Biocytogen+and+Whitehawk+Therapeutics+Enter+Global+Collaboration+for+Bispecific+Antibody+ADC+Development/26738739.html <p> BOSTON &amp; MORRISTOWN, N.J.--(BUSINESS WIRE)-- Biocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. (“Whitehawk,” Nasdaq: WHWK) today announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocytogen will provide access to up to five bispecific antibodies using its proprietary RenLite® platform, and Whitehawk will evaluate these in combination with its ADC linker-payload platform technologies. Whitehawk then has the option to advance any resulting BsADC candidates as part of its pipeline. </p><p> Based on a common light-chain design, RenLite® supports the discovery, screening, and optimization of fully human bispecific antibodies across diverse target combinations, while reducing the risk http://www.streetinsider.com/Press+Releases/Biocytogen+and+Whitehawk+Therapeutics+Enter+Global+Collaboration+for+Bispecific+Antibody+ADC+Development/26738739.html Tue, 07 Jul 2026 08:00:00 -0400 02315 688796 O.37125755 O.55107896 WHWK http://www.streetinsider.com/Press+Releases/Biocytogen+and+Whitehawk+Therapeutics+Enter+Global+Collaboration+for+Bispecific+Antibody+ADC+Development/26738739.html <p> BOSTON &amp; MORRISTOWN, N.J.--(BUSINESS WIRE)-- Biocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. (“Whitehawk,” Nasdaq: WHWK) today announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocytogen will provide access to up to five bispecific antibodies using its proprietary RenLite® platform, and Whitehawk will evaluate these in combination with its ADC linker-payload platform technologies. Whitehawk then has the option to advance any resulting BsADC candidates as part of its pipeline. </p><p> Based on a common light-chain design, RenLite® supports the discovery, screening, and optimization of fully human bispecific antibodies across diverse target combinations, while reducing the risk http://www.streetinsider.com/Press+Releases/Biocytogen+and+Whitehawk+Therapeutics+Enter+Global+Collaboration+for+Bispecific+Antibody+ADC+Development/26738739.html Tue, 07 Jul 2026 08:00:00 -0400 02315 688796 O.37125755 O.55107896 WHWK http://www.streetinsider.com/Press+Releases/Biocytogen+and+Whitehawk+Therapeutics+Enter+Global+Collaboration+for+Bispecific+Antibody+ADC+Development/26738739.html <p> BOSTON &amp; MORRISTOWN, N.J.--(BUSINESS WIRE)-- Biocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. (“Whitehawk,” Nasdaq: WHWK) today announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocytogen will provide access to up to five bispecific antibodies using its proprietary RenLite® platform, and Whitehawk will evaluate these in combination with its ADC linker-payload platform technologies. Whitehawk then has the option to advance any resulting BsADC candidates as part of its pipeline. </p><p> Based on a common light-chain design, RenLite® supports the discovery, screening, and optimization of fully human bispecific antibodies across diverse target combinations, while reducing the risk http://www.streetinsider.com/Press+Releases/Biocytogen+and+Whitehawk+Therapeutics+Enter+Global+Collaboration+for+Bispecific+Antibody+ADC+Development/26738739.html Tue, 07 Jul 2026 08:00:00 -0400 02315 688796 O.37125755 O.55107896 WHWK http://www.streetinsider.com/Business+Wire/Biocytogen+and+Whitehawk+Therapeutics+Enter+Global+Collaboration+for+Bispecific+Antibody+ADC+Development/26738739.html <p> BOSTON &amp; MORRISTOWN, N.J.--(BUSINESS WIRE)-- Biocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. (“Whitehawk,” Nasdaq: WHWK) today announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocytogen will provide access to up to five bispecific antibodies using its proprietary RenLite® platform, and Whitehawk will evaluate these in combination with its ADC linker-payload platform technologies. Whitehawk then has the option to advance any resulting BsADC candidates as part of its pipeline. </p><p> Based on a common light-chain design, RenLite® supports the discovery, screening, and optimization of fully human bispecific antibodies across diverse target combinations, while reducing the risk http://www.streetinsider.com/Business+Wire/Biocytogen+and+Whitehawk+Therapeutics+Enter+Global+Collaboration+for+Bispecific+Antibody+ADC+Development/26738739.html Tue, 07 Jul 2026 08:00:00 -0400 02315 688796 O.37125755 O.55107896 WHWK http://www.streetinsider.com/Business+Wire/Biocytogen+and+Whitehawk+Therapeutics+Enter+Global+Collaboration+for+Bispecific+Antibody+ADC+Development/26738739.html <p> BOSTON &amp; MORRISTOWN, N.J.--(BUSINESS WIRE)-- Biocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. (“Whitehawk,” Nasdaq: WHWK) today announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocytogen will provide access to up to five bispecific antibodies using its proprietary RenLite® platform, and Whitehawk will evaluate these in combination with its ADC linker-payload platform technologies. Whitehawk then has the option to advance any resulting BsADC candidates as part of its pipeline. </p><p> Based on a common light-chain design, RenLite® supports the discovery, screening, and optimization of fully human bispecific antibodies across diverse target combinations, while reducing the risk http://www.streetinsider.com/Business+Wire/Biocytogen+and+Whitehawk+Therapeutics+Enter+Global+Collaboration+for+Bispecific+Antibody+ADC+Development/26738739.html Tue, 07 Jul 2026 08:00:00 -0400 02315 688796 O.37125755 O.55107896 WHWK http://www.streetinsider.com/Business+Wire/Biocytogen+and+Whitehawk+Therapeutics+Enter+Global+Collaboration+for+Bispecific+Antibody+ADC+Development/26738739.html <p> BOSTON &amp; MORRISTOWN, N.J.--(BUSINESS WIRE)-- Biocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. (“Whitehawk,” Nasdaq: WHWK) today announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocytogen will provide access to up to five bispecific antibodies using its proprietary RenLite® platform, and Whitehawk will evaluate these in combination with its ADC linker-payload platform technologies. Whitehawk then has the option to advance any resulting BsADC candidates as part of its pipeline. </p><p> Based on a common light-chain design, RenLite® supports the discovery, screening, and optimization of fully human bispecific antibodies across diverse target combinations, while reducing the risk http://www.streetinsider.com/Business+Wire/Biocytogen+and+Whitehawk+Therapeutics+Enter+Global+Collaboration+for+Bispecific+Antibody+ADC+Development/26738739.html Tue, 07 Jul 2026 08:00:00 -0400 02315 688796 O.37125755 O.55107896 WHWK http://www.streetinsider.com/Business+Wire/Biocytogen+and+Whitehawk+Therapeutics+Enter+Global+Collaboration+for+Bispecific+Antibody+ADC+Development/26738739.html <p> BOSTON &amp; MORRISTOWN, N.J.--(BUSINESS WIRE)-- Biocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. (“Whitehawk,” Nasdaq: WHWK) today announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocytogen will provide access to up to five bispecific antibodies using its proprietary RenLite® platform, and Whitehawk will evaluate these in combination with its ADC linker-payload platform technologies. Whitehawk then has the option to advance any resulting BsADC candidates as part of its pipeline. </p><p> Based on a common light-chain design, RenLite® supports the discovery, screening, and optimization of fully human bispecific antibodies across diverse target combinations, while reducing the risk http://www.streetinsider.com/Business+Wire/Biocytogen+and+Whitehawk+Therapeutics+Enter+Global+Collaboration+for+Bispecific+Antibody+ADC+Development/26738739.html Tue, 07 Jul 2026 08:00:00 -0400 02315 688796 O.37125755 O.55107896 WHWK http://www.streetinsider.com/Business+Wire/Biocytogen+and+Whitehawk+Therapeutics+Enter+Global+Collaboration+for+Bispecific+Antibody+ADC+Development/26738739.html <p> BOSTON &amp; MORRISTOWN, N.J.--(BUSINESS WIRE)-- Biocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. (“Whitehawk,” Nasdaq: WHWK) today announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocytogen will provide access to up to five bispecific antibodies using its proprietary RenLite® platform, and Whitehawk will evaluate these in combination with its ADC linker-payload platform technologies. Whitehawk then has the option to advance any resulting BsADC candidates as part of its pipeline. </p><p> Based on a common light-chain design, RenLite® supports the discovery, screening, and optimization of fully human bispecific antibodies across diverse target combinations, while reducing the risk http://www.streetinsider.com/Business+Wire/Biocytogen+and+Whitehawk+Therapeutics+Enter+Global+Collaboration+for+Bispecific+Antibody+ADC+Development/26738739.html Tue, 07 Jul 2026 08:00:00 -0400 02315 688796 O.37125755 O.55107896 WHWK http://www.streetinsider.com/New+Coverage/B.Riley+Starts+Whitehawk+Therapeutics+%28WHWK%29+at+Buy/26688923.html (Updated - June 25, 2026 8:46 AM EDT) <p>B.Riley analyst Yuan Zhi initiates coverage on Whitehawk Therapeutics (NASDAQ: WHWK) with a Buy rating and a price target of $10.00.</p><p>The analyst commented: "We are initiating coverage of Whitehawk Therapeutics Inc. (WHWK) with a Buy rating and a $10 price target. WHWK is a clinical-stage oncology company advancing a three-asset, next generation antibody-drug conjugate (ADC) portfolio in-licensed from WuXi Biologics in early 2025. This in-licensing was ahead of many others that in-licensed assets from China in the last 18 months at a significant discount. The ADC platform improves on the narrow therapeutic index http://www.streetinsider.com/New+Coverage/B.Riley+Starts+Whitehawk+Therapeutics+%28WHWK%29+at+Buy/26688923.html Thu, 25 Jun 2026 08:46:33 -0400 WHWK http://www.streetinsider.com/Analyst+Comments/B.Riley+Starts+Whitehawk+Therapeutics+%28WHWK%29+at+Buy/26688923.html (Updated - June 25, 2026 8:46 AM EDT) <p>B.Riley analyst Yuan Zhi initiates coverage on Whitehawk Therapeutics (NASDAQ: WHWK) with a Buy rating and a price target of $10.00.</p><p>The analyst commented: "We are initiating coverage of Whitehawk Therapeutics Inc. (WHWK) with a Buy rating and a $10 price target. WHWK is a clinical-stage oncology company advancing a three-asset, next generation antibody-drug conjugate (ADC) portfolio in-licensed from WuXi Biologics in early 2025. This in-licensing was ahead of many others that in-licensed assets from China in the last 18 months at a significant discount. The ADC platform improves on the narrow therapeutic index http://www.streetinsider.com/Analyst+Comments/B.Riley+Starts+Whitehawk+Therapeutics+%28WHWK%29+at+Buy/26688923.html Thu, 25 Jun 2026 08:46:33 -0400 WHWK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Zhao+Baiteng/26648723.html si-local-file:///var/storage/secattach/20260615/26648723.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Zhao+Baiteng/26648723.html Mon, 15 Jun 2026 17:27:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Zhao+Baiteng/26648723.html si-local-file:///var/storage/secattach/20260615/26648723.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Zhao+Baiteng/26648723.html Mon, 15 Jun 2026 17:27:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Reeve+Emma/26648712.html si-local-file:///var/storage/secattach/20260615/26648712.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Reeve+Emma/26648712.html Mon, 15 Jun 2026 17:26:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Reeve+Emma/26648712.html si-local-file:///var/storage/secattach/20260615/26648712.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Reeve+Emma/26648712.html Mon, 15 Jun 2026 17:26:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Maroun+Richard+E/26648691.html si-local-file:///var/storage/secattach/20260615/26648691.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Maroun+Richard+E/26648691.html Mon, 15 Jun 2026 17:24:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Maroun+Richard+E/26648691.html si-local-file:///var/storage/secattach/20260615/26648691.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Maroun+Richard+E/26648691.html Mon, 15 Jun 2026 17:24:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Hirmand+Mohammad/26648672.html si-local-file:///var/storage/secattach/20260615/26648672.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Hirmand+Mohammad/26648672.html Mon, 15 Jun 2026 17:23:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Hirmand+Mohammad/26648672.html si-local-file:///var/storage/secattach/20260615/26648672.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Hirmand+Mohammad/26648672.html Mon, 15 Jun 2026 17:23:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Castelein+Caley/26648656.html si-local-file:///var/storage/secattach/20260615/26648656.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Castelein+Caley/26648656.html Mon, 15 Jun 2026 17:22:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Castelein+Caley/26648656.html si-local-file:///var/storage/secattach/20260615/26648656.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Castelein+Caley/26648656.html Mon, 15 Jun 2026 17:22:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Desai+Neil/26648663.html si-local-file:///var/storage/secattach/20260615/26648663.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Desai+Neil/26648663.html Mon, 15 Jun 2026 17:22:00 -0400 O.37125755 WHWK